On Tuesday, August 19, 2025, United States District Judge Zahid N. Quraishi of the District of New Jersey granted final approval of Indirect Purchaser Plaintiffs’ $2.25 million class-action settlement with Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd. (collectively, “Teva”) in the Effexor XR Antitrust Litigation. This brings the total amount recovered for end-payors in the case to $27,750,000.
This settlement resolves claims that Teva engaged in anticompetitive practices to delay the entry of generic versions of the drug Effexor XR, ending litigation that had been ongoing for over a decade. Co-Defendants Wyeth—a/k/a Wyeth LLC, f/k/a Wyeth, Inc., f/k/a American Home Products—Wyeth Pharmaceuticals, Inc., Wyeth Pharmaceuticals Company, and Wyeth-Whitehall Pharmaceuticals previously agreed to a $25.5 million class-action settlement, which was approved by the court in late 2024.
The lawsuit, originally brought in 2011, alleged that Defendants engaged in anticompetitive conduct to delay the release of generic alternatives to Effexor XR. According to Plaintiffs, these actions kept prices for the medication artificially inflated, negatively impacting indirect purchasers of the drugs, including consumers and insurers.
WBE served on the Indirect Purchaser Plaintiffs’ Executive Committee in this case, Effexor XR Antitrust Litigation, No. 11-cv-05479, in the U.S. District Court for the District of New Jersey. For the purposes of the settlement, the court certified a class of indirect purchasers from multiple states and named WBE as one of the Class Counsel for the Settlement Class.
For more information on this settlement, including the full class definition and who is not included, please visit https://www.effexorxrindirectsettlement.com.